Therapeutic and transmission-blocking efficacy of dihydroartemisinin/ piperaquine and chloroquine against Plasmodium vivax Malaria, Cambodia
JournalEmerging Infectious Diseases
PublisherCenters for Disease Control and Prevention (CDC)
MetadataShow full item record
AbstractWe assessed the efficacy of standard 3-day courses of chloroquine and dihydroartemisinin/piperaquine against Plasmodium vivax malaria. Compared with chloroquine, dihydroartemisinin/piperaquine was faster in clearing asexual P. vivax parasites and blocking human-to-mosquito transmission. This drug combination was also more effective in preventing potential recurrences for >2 months. Copyright 2018, Centers for Disease Control and Prevention (CDC). All rights reserved.
SponsorsThis study was supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant R01 434 A103328) and the Institut Pasteur (grant PTR 2014-490). A.V. was supported by a Calmette and Yersin fellowship from the Institut Pasteur International Network.
Drug Therapy, Combination
Malaria, Vivax--prevention & control
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85050398698&doi=10.3201%2feid2408.170768&partnerID=40&md5=5446b825781354cdb60ad5902847f51a; http://hdl.handle.net/10713/9468